Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SUN-111
- Development stage
- Unknown
- Lead developer
- Sundance Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SUN-111 is an orally bioavailable small molecule inhibitor of Tyrosine Kinase 2 (TYK2) being developed by Sundance Biosciences. TYK2 is a member of the Janus kinase (JAK) family that mediates signaling for key inflammatory cytokines, including IL-12, IL-23, and Type I interferons. By selectively targeting TYK2, SUN-111 aims to modulate these pathways to treat peripheral inflammatory conditions while potentially avoiding the off-target effects associated with non-selective JAK inhibitors (such as JAK1, JAK2, or JAK3 inhibition). The drug is currently in Phase 1 clinical development.
- Other names
- SUN-111SUN111SUN 111
02
Targets
TYK2 (Tyrosine kinase 2)
Beyond the preview
Go deeper on SUN-111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SUN-111.